FGF19 Gene Overexpression clinical trials at UCSF
1 research study open to eligible people
FGF19 gene overexpression is when the FGF19 gene makes too much protein. UCSF is running a phase one study to check safety and side effects. UCSF is focusing on adults with advanced liver and other solid tumors that have FGF or FGFR changes.
Showing trials for
Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
open to eligible people ages 18 years and up
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
San Francisco, California and other locations
Last updated: